Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with ...
In this week's column, OpenAI buys TBPN, TMZ ambushes Congress, NYT cuts ties with writer, DC media scramble and a ‘60 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results